Skip navigation
Search
Sciety application settings
Home
Groups
Explore
Newsletter
About
Log In
Sign Up
SGLT2 inhibitor empagliflozin ameliorates tubulointerstitial fibrosis in DKD by downregulating renal tubular PKM2
Xiang Cai
Huanyi Cao
Meijun Wang
Piaojian Yu
Xiaoqi Liang
Hua Liang
Fen Xu
Mengyin Cai
Read the full article
See related articles
Listed in
This article is not in any list yet, why not save it to one of your lists.
Log in to save this article
Abstract
No abstract available
Article activity feed
Version published to 10.1007/s00018-025-05688-8
Apr 16, 2025
Version published to 10.21203/rs.3.rs-5563608/v1 on Research Square
Apr 2, 2025
Related articles
Bidirectional Upregulation of Klotho by Triiodothyronine and Baicalein: Mitigating Chronic Kidney Disease and Associated Complications in Aged BALB/c Mice
This article has 4 authors:
Saswat Kumar Mohanty
Vikas Kumar Sahu
Bhanu Pratap Singh
Kitlangki Suchiang
WITHDRAWN: Liraglutide suppresses ferroptosis by activating NRF2 target in type 2 diabetic cardiomyopathy
This article has 7 authors:
xuepin chen
Jun Guan
Hongyan Dai
Yan Gao
xiaochen you
tianying wang
Guo an Wang
The sodium/glucose cotransporter 2 inhibitor empagliflozin is a pharmacological chaperone of cardiac Na
v
1.5 channels
This article has 13 authors:
Jakob Sauer
Jessica Marksteiner
Martin Hohenegger
Hannes Todt
Helmut Kubista
Christopher Dostal
Attila Kiss
Bruno K. Podesser
Isabella Salzer
Xaver Koenig
Anna Stary-Weinzinger
Karlheinz Hilber
Oliver Kudlacek
Site navigation links
Home
Groups
Explore
Newsletter
About
Log In
Sign Up